Cancer, Superficial Vein Thrombosis, Venous Thrombosis
Conditions
Keywords
Superficial vein thrombosis, cancer, venous thrombosis
Brief summary
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 * Patient affiliated to a social security scheme * Patient who understands French * Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old. * Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Exclusion criteria
* Patients under legal protection * Patients with concomitant pulmonary embolism * Patient with proximal or distal deep vein thrombosis * Patient treated with anticoagulant therapy for another indication * Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding. * Patient opposed to participation in research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| risk (in %) of recurrence of VTE | at 3-month follow-up | risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT. |
Secondary
| Measure | Time frame |
|---|---|
| association (%) between initial treatment and the risk of SVT recurrence | at 3 months |
| Association (%) between initial treatment and the occurrence of pulmonary embolism (PE) | at 12 months |
| Association (%) between initial treatment and the occurrence of DVT | at 3 months |
| association (%) between initial treatment and bleeding events | at 6 months |
| association(%) between initial treatment and all-cause death | at 3 months |
| rates of recurrence of symptomatic vs. incidental VTE | at 3 months |
| rate of confirmed cancer in patients with TVS suspected of having cancer. | at 12 months |
Countries
France
Contacts
CONTACTSimon SOUDET, Dr
Outcome results
None listed